The Ensign Group's third quarter drew a positive market reaction despite missing Wall Street's revenue and earnings per share expectations, as investors looked beyond headline numbers to underlying business momentum. Management attributed the quarter's performance to continued gains in occupancy and skilled mix, with CEO Barry Port highlighting a "relentless patient-focused culture" and ongoing success in integrating new operations. The company's clinical outcomes, validated by above-average quality ratings and lower staff turnover, played a significant role in attracting more complex cases and expanding relationships with managed care partners.
Is now the time to buy ENSG? Find out in our full research report (it's free).
The Ensign Group (ENSG) Q3 2026 highlights:
-
Revenue $1.48 billion vs S&P analysts' estimates of $1.60 billion (14.5% year-on-year growth, 7.1% miss)
-
EPS (GAAP) $1.76 vs analyst expectations of $1.81 (2.8% miss)
-
Adjusted EBITDA $190.7 million vs analyst estimates of $186.2 million (12.9% margin, 2.4% beat)
-
Revenue guidance The company slightly lifted its revenue guidance for the full year to $5.91 billion at the midpoint from $5.90 billion
-
GAAP EPS guida...